Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shah, A. A.
Right arrow Articles by Fitzgerald, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, A. A.
Right arrow Articles by Fitzgerald, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology, Vol 38, 19-23, Copyright © 1999 by British Society for Rheumatology

REVIEWS

The in vivo assessment of nimesulide cyclooxygenase-2 selectivity

AA Shah, FE Murray and DJ Fitzgerald
Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin.

In man, nimesulide selectively inhibits cyclooxygenase-2 (COX-2) with little effect on haemostatic function or gastric prostaglandin formation. It causes significantly less gastrointestinal injury than naproxen, but has anti-inflammatory efficacy similar to that of naproxen and other currently available non-steroidal anti-inflammatory drugs. Naproxen suppressed arachidonic-acid-mediated platelet aggregation, reduced serum thromboxane B2 levels by 98% throughout the treatment period and reduced gastric mucosal prostaglandins (PGE2 and 6- keto-PGF1alpha) production by an average of 80%. This contrasts with nimesulide: platelet aggregation was not significantly affected, thromboxane B2 levels were only 29% lower and the gastric mucosal prostaglandins were inhibited in the order of approximately 20%. During the treatment period, both nimesulide and naproxen significantly inhibited COX-2-dependent PGE2 synthesis in the whole blood; however, naproxen had a lesser effect than nimesulide.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
M. E. Patterson, J. J. Mullins, and K. D. Mitchell
Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F205 - F211.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. L. Opay, C. R. Mouton, J. J. Mullins, and K. D. Mitchell
Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension
Am J Physiol Renal Physiol, September 1, 2006; 291(3): F612 - F618.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
D. L. Simmons, R. M. Botting, and T. Hla
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
V. Rozenfeld, L. Chagan, and E. Kleyman
The Year in Review: Rheumatology
Journal of Pharmacy Practice, February 1, 2001; 14(1): 54 - 69.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.